Testing for inherited susceptibility to cancer has been available for over 20 years, but uptake remains low among even patients at high risk. It is now well-established that between 1 in 5 and 1 in 20 patients with breast, ovarian, endometrial or colorectal cancers has a deleterious germline mutation conferring inherited susceptibility to cancer.
Despite advances in genetic testing technologies and a decrease in the cost of testing, the uptake of testing among eligible patients with cancer remains unacceptably low. There is thus a gap between actual and ideal care with implications for primary and secondary cancer prevention and treatment in people with an inherited susceptibility and their family members.
The MiGHT study leverages diverse, statewide partnerships among healthcare and public health entities to employ both practice- and patient-level interventions to improve family history collection and uptake of genetic testing, with the overarching goal of reducing cancer morbidity and mortality.